SI2034999T1 - DHA estri in uporaba le-teh pri zdravljenju in preprečevanju kardiovaskularnih bolezni - Google Patents

DHA estri in uporaba le-teh pri zdravljenju in preprečevanju kardiovaskularnih bolezni

Info

Publication number: SI2034999T1
Authority: SI; Slovenia
Prior art keywords: prevention; treatment; cardiovascular diseases; dha esters; dha
Prior art date: 2006-06-23

Application number

SI200730469T

Other languages

English (en)

Inventor

Frederique Brune

Andre Delhon

Jean Gardette

Jean Francois Patoiseau

Alain Marty

Etienne Severac

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-23

Filing date

2007-06-22

Publication date

2011-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2034999(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-22 Application filed by Pf Medicament filed Critical Pf Medicament

2011-02-28 Publication of SI2034999T1 publication Critical patent/SI2034999T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Public Health (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SI200730469T 2006-06-23 2007-06-22 DHA estri in uporaba le-teh pri zdravljenju in preprečevanju kardiovaskularnih bolezni SI2034999T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0605649A FR2902659A1 (fr)	2006-06-23	2006-06-23	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (en)	2006-06-23	2007-06-22	Dha esters and use thereof in treatment and prevention of cardiovascular disease
EP07765584A EP2034999B9 (en)	2006-06-23	2007-06-22	Dha esters and use thereof in the treatment and the prevention of cardiovascular diseases

Publications (1)

Publication Number	Publication Date
SI2034999T1 true SI2034999T1 (sl)	2011-02-28

Family

ID=37686083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200730469T SI2034999T1 (sl)	2006-06-23	2007-06-22	DHA estri in uporaba le-teh pri zdravljenju in preprečevanju kardiovaskularnih bolezni

Country Status (38)

Country	Link
US (2)	US8034377B2 (sl)
EP (1)	EP2034999B9 (sl)
JP (1)	JP5053372B2 (sl)
KR (1)	KR101380128B1 (sl)
CN (1)	CN101472590A (sl)
AR (1)	AR061622A1 (sl)
AT (1)	ATE489091T1 (sl)
AU (1)	AU2007262958B2 (sl)
BR (1)	BRPI0713725A2 (sl)
CA (1)	CA2655570C (sl)
CL (1)	CL2010001123A1 (sl)
CO (1)	CO6150156A2 (sl)
CR (1)	CR10507A (sl)
DE (1)	DE602007010776D1 (sl)
DK (1)	DK2034999T3 (sl)
EC (1)	ECSP099039A (sl)
ES (1)	ES2355611T3 (sl)
FR (1)	FR2902659A1 (sl)
GE (1)	GEP20125464B (sl)
HN (1)	HN2008001771A (sl)
HR (1)	HRP20110086T1 (sl)
IL (1)	IL195562A (sl)
MA (1)	MA30584B1 (sl)
MX (1)	MX2009000103A (sl)
MY (1)	MY145985A (sl)
NO (1)	NO20090334L (sl)
NZ (1)	NZ573454A (sl)
PL (1)	PL2034999T3 (sl)
PT (1)	PT2034999E (sl)
RS (1)	RS51629B (sl)
RU (1)	RU2451672C2 (sl)
SA (1)	SA07280345B1 (sl)
SI (1)	SI2034999T1 (sl)
TN (1)	TNSN08527A1 (sl)
TW (1)	TWI389888B (sl)
UA (1)	UA96156C2 (sl)
WO (1)	WO2007147899A2 (sl)
ZA (1)	ZA200900334B (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2334536B1 (es) *	2008-04-11	2011-01-24	Universidad Complutense De Madrid	Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) *	2009-08-11	2011-09-30	Pf Medicament	Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
JP6324720B2 (ja)	2010-06-18	2018-05-16	エックスバイオテク, インコーポレイテッドXbiotech, Inc.	関節炎治療
FR2963790B1 (fr) *	2010-08-11	2012-09-28	Pf Medicament	Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
KR102748255B1 (ko)	2010-08-23	2024-12-31	엑스바이오테크 인코포레이티드	종양성 질병들에 대한 치료
US9724409B2 (en)	2011-04-01	2017-08-08	Xbiotech, Inc.	Treatment of inflammatory skin disease
CN102757444B (zh) *	2011-04-29	2016-02-10	南京信诺泰医药有限公司	具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) *	2012-11-27	2017-04-28	Pf Medicament	Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) *	2014-08-12	2016-02-18	Praj Industries Limited	Process for the preparation of triglycerides of epa and dha
US10441087B2 (en)	2015-02-24	2019-10-15	Sleep Number Corporation	Mattress with adjustable firmness
KR20190117579A (ko)	2017-02-16	2019-10-16	엑스바이오테크, 인크.	화농성 한선염의 치료
US11116731B2 (en) *	2017-02-20	2021-09-14	Brd. of Sup. of LSU and A &M College	Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
CN110950881A (zh) *	2018-09-27	2020-04-03	中国科学院上海药物研究所	一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL133049C (sl)	1966-02-24
JPS5967263A (ja)	1982-10-07	1984-04-16	Terumo Corp	ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja)	1982-10-08	1984-04-16	Terumo Corp	血小板凝集抑制剤
EP0125252A1 (de)	1982-11-16	1984-11-21	MOTSCHAN, Georges	Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine
JPS6034947A (ja) *	1983-08-05	1985-02-22	Terumo Corp	ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) *	1993-01-06	1993-03-03	Scotia Holdings Plc	Compositions containing esters of unsaturated fatty acids
US5760081A (en)	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
DK0823897T3 (da)	1995-05-01	2004-12-06	Scarista Ltd	Nicotinsyreestere og farmaceutiske præparater indeholdende disse
IL118092A0 (en)	1995-05-03	1996-09-12	Smithkline Beecham Plc	Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US5795909A (en)	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
AUPQ480399A0 (en)	1999-12-22	2000-02-03	Commonwealth Scientific And Industrial Research Organisation	Unsaturated fatty acids and their uses in therapy
ES2246769T3 (es)	2000-05-22	2006-03-01	Pro Aparts - Investimentos E Consultoria Lda	Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
ITMI20010129A1 (it)	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) *	2001-09-12	2010-04-27	Xanodyne Pharmaceuticals, Inc.	Vitamin/mineral compositions with DHA
US8729124B2 (en)	2002-03-05	2014-05-20	Pronova Biopharma Norge As	Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) *	2002-11-26	2004-05-27	Victorix Assets Ltd	Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
EP1466597A1 (en) *	2003-04-07	2004-10-13	Clinigenetics	Use of dha esters to control or prevent cardiovascular diseases
WO2004091603A1 (fr) *	2003-04-07	2004-10-28	Clinigenetics	Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
RU2005135565A (ru)	2003-04-17	2006-07-27	БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE)	Поливитаминная и минеральная добавка для беременных женщин

2006
- 2006-06-23 FR FR0605649A patent/FR2902659A1/fr active Pending
2007
- 2007-06-22 TW TW096122472A patent/TWI389888B/zh not_active IP Right Cessation
- 2007-06-22 CN CNA2007800228209A patent/CN101472590A/zh active Pending
- 2007-06-22 JP JP2009517144A patent/JP5053372B2/ja not_active Expired - Fee Related
- 2007-06-22 CA CA2655570A patent/CA2655570C/en not_active Expired - Fee Related
- 2007-06-22 SI SI200730469T patent/SI2034999T1/sl unknown
- 2007-06-22 PT PT07765584T patent/PT2034999E/pt unknown
- 2007-06-22 AR ARP070102779A patent/AR061622A1/es not_active Application Discontinuation
- 2007-06-22 ES ES07765584T patent/ES2355611T3/es active Active
- 2007-06-22 RU RU2008152248/04A patent/RU2451672C2/ru not_active IP Right Cessation
- 2007-06-22 DE DE602007010776T patent/DE602007010776D1/de active Active
- 2007-06-22 DK DK07765584.3T patent/DK2034999T3/da active
- 2007-06-22 US US12/305,162 patent/US8034377B2/en not_active Expired - Fee Related
- 2007-06-22 GE GEAP200711074A patent/GEP20125464B/en unknown
- 2007-06-22 UA UAA200900468A patent/UA96156C2/ru unknown
- 2007-06-22 AT AT07765584T patent/ATE489091T1/de active
- 2007-06-22 EP EP07765584A patent/EP2034999B9/en active Active
- 2007-06-22 WO PCT/EP2007/056277 patent/WO2007147899A2/en not_active Ceased
- 2007-06-22 MY MYPI20084785A patent/MY145985A/en unknown
- 2007-06-22 MX MX2009000103A patent/MX2009000103A/es active IP Right Grant
- 2007-06-22 KR KR1020097001053A patent/KR101380128B1/ko not_active Expired - Fee Related
- 2007-06-22 BR BRPI0713725-7A patent/BRPI0713725A2/pt not_active IP Right Cessation
- 2007-06-22 HR HR20110086T patent/HRP20110086T1/hr unknown
- 2007-06-22 PL PL07765584T patent/PL2034999T3/pl unknown
- 2007-06-22 AU AU2007262958A patent/AU2007262958B2/en not_active Ceased
- 2007-06-22 RS RS20110091A patent/RS51629B/sr unknown
- 2007-06-22 NZ NZ573454A patent/NZ573454A/en not_active IP Right Cessation
- 2007-06-23 SA SA07280345A patent/SA07280345B1/ar unknown
2008
- 2008-11-27 HN HN2008001771A patent/HN2008001771A/es unknown
- 2008-11-27 IL IL195562A patent/IL195562A/en active IP Right Grant
- 2008-12-12 CR CR10507A patent/CR10507A/es unknown
- 2008-12-19 TN TNP2008000527A patent/TNSN08527A1/en unknown
2009
- 2009-01-07 EC EC2009009039A patent/ECSP099039A/es unknown
- 2009-01-09 MA MA31561A patent/MA30584B1/fr unknown
- 2009-01-15 ZA ZA2009/00334A patent/ZA200900334B/en unknown
- 2009-01-21 NO NO20090334A patent/NO20090334L/no not_active Application Discontinuation
- 2009-01-22 CO CO09005510A patent/CO6150156A2/es unknown
2010
- 2010-10-13 CL CL2010001123A patent/CL2010001123A1/es unknown
2011
- 2011-06-13 US US13/159,022 patent/US8227479B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CO6150156A2 (es)	2010-04-20
EP2034999B9 (en)	2011-03-09
GEP20125464B (en)	2012-04-10
JP5053372B2 (ja)	2012-10-17
WO2007147899A2 (en)	2007-12-27
DE602007010776D1 (de)	2011-01-05
AR061622A1 (es)	2008-09-10
MA30584B1 (fr)	2009-07-01
US8227479B2 (en)	2012-07-24
NZ573454A (en)	2010-10-29
TW200811108A (en)	2008-03-01
CA2655570A1 (en)	2007-12-27
TWI389888B (zh)	2013-03-21
CR10507A (es)	2009-02-05
CL2010001123A1 (es)	2011-03-25
HRP20110086T1 (hr)	2011-03-31
JP2009544576A (ja)	2009-12-17
PL2034999T3 (pl)	2011-05-31
ATE489091T1 (de)	2010-12-15
US20090312354A1 (en)	2009-12-17
RU2451672C2 (ru)	2012-05-27
IL195562A0 (en)	2009-09-01
HN2008001771A (es)	2011-01-24
MX2009000103A (es)	2009-01-23
KR20090024794A (ko)	2009-03-09
WO2007147899A3 (en)	2008-03-13
EP2034999B1 (en)	2010-11-24
WO2007147899B1 (en)	2008-05-02
ECSP099039A (es)	2009-02-27
NO20090334L (no)	2009-03-04
ZA200900334B (en)	2009-12-30
CA2655570C (en)	2015-09-08
EP2034999A2 (en)	2009-03-18
BRPI0713725A2 (pt)	2012-10-30
US20110237613A1 (en)	2011-09-29
PT2034999E (pt)	2011-01-19
RU2008152248A (ru)	2010-07-27
FR2902659A1 (fr)	2007-12-28
UA96156C2 (ru)	2011-10-10
AU2007262958B2 (en)	2011-10-27
TNSN08527A1 (en)	2010-04-14
IL195562A (en)	2012-06-28
RS51629B (sr)	2011-08-31
KR101380128B1 (ko)	2014-04-11
CN101472590A (zh)	2009-07-01
ES2355611T3 (es)	2011-03-29
AU2007262958A1 (en)	2007-12-27
SA07280345B1 (ar)	2011-01-15
DK2034999T3 (da)	2011-01-24
MY145985A (en)	2012-05-31
US8034377B2 (en)	2011-10-11

Publication	Publication Date	Title
PL2034999T3 (pl)	2011-05-31	Estry DHA i ich zastosowanie w leczeniu i zapobieganiu chorobom sercowo-naczyniowym
PL2546253T3 (pl)	2015-08-31	Podstawione dihydropirazolony do leczenia schorzeń sercowo-naczyniowych i hematologicznych
SI2118074T1 (sl)	2014-05-30	Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
IL199045A0 (en)	2010-03-28	Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP1919468A4 (en)	2010-02-10	TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF
EP2007385A4 (en)	2010-08-18	CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
ZA200900051B (en)	2010-01-27	Modulators of metabolism and the treatment of disorders related thereto
ZA200900055B (en)	2009-12-30	Modulators of metabolism and the treatment of disorders related thereto
IL206080A0 (en)	2010-11-30	Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
EP2079526A4 (en)	2010-01-13	COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
PL2297106T3 (pl)	2015-01-30	Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
AU2007243282A8 (en)	2008-11-27	Compositions and methods for the treatment of cardiovascular disease
IL201885A0 (en)	2011-08-01	Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations
EP2240193A4 (en)	2011-04-27	COMPOSITION COMPRISING LINDERA OBTUSILOBA EXTRACTS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
EP2001488A4 (en)	2009-11-25	PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
IL197237A0 (en)	2009-12-24	Use of c7 sugars in prevention and treatment of mycoses
EP1958522A4 (en)	2010-04-28	FUNCTIONAL FOOD WITH POSITIVE EFFECTS IN THE PREVENTION OF CARDIOVASCULAR DISEASES
IL201426A0 (en)	2010-05-31	Drug combination and its use in the treatment of muscle loss
IL198493A0 (en)	2010-02-17	Use of epothilones in the treatment of osteoporosis and related diseases
PT2182954T (pt)	2019-02-06	Utilização de ácidos nor-biliares no tratamento de arteriosclerose
EP1997487A4 (en)	2013-11-06	PRODUCT USED IN THE PREVENTION AND TREATMENT OF CARDIAC DISEASES, CANCER AND INFLAMMATORY DISEASES
GB0604826D0 (en)	2006-04-19	The treatment of inflammatory disorders and pain
ZA200904382B (en)	2010-08-25	Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases
ZA200900543B (en)	2010-03-31	Compositions and methods for the treatment of mucormycosis and other fungal diseases
GB0604822D0 (en)	2006-04-19	The treatment of inflammatory disorders and pain